|
1. Biologie
|
|
|
|
3. Prévention
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5. Traitements
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.12 Immunothérapies
|
|
|
Can T cells be unleashed to attack skin tumors? [UNC]
|
|
|
|
|
|
UNC
Lineberger researchers are planning to launch an investigator-initiated
clinical trial year to assess whether the combination denosumab with
the checkpoint inhibitor pembrolizumab is more effective than
pembrolizumab alone for treating patients with advanced melanoma.
|
|
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
Novartis Is Said to Eye Deal for Radioactive-Drug Maker AAA [Bloomberg]
|
|
|
|
|
|
AAA
makes radiopharmaceuticals, or radioactive drugs, used to diagnose and
treat diseases such as cancer. Italian academics founded the company in
2002 as a spinoff of the European Organization for Nuclear Research, or
CERN. AAA is based in Saint-Genis-Pouilly, a French town just outside
Geneva.
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
Deciphera IPO Drums Up $128M for Cancer Drug Studies [Xconomy]
|
|
|
|
|
|
Deciphera
develops drugs that block kinases, enzymes that play a key role in the
growth and spread of cancers. Its lead drug, called DCC-2618, blocks a
full range of kinases that drive gastrointestinal stromal tumors, or
GIST. The compound is in a Phase 1 clinical trial.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
FDA approves new treatment for certain advanced or metastatic breast cancers [FDA]
|
|
|
|
|
|
Verzenio
(abemaciclib) works by blocking certain molecules (known as
cyclin-dependent kinases 4 and 6), involved in promoting the growth of
cancer cells. There are two other drugs in this class that are approved
for certain patients with breast cancer, palbociclib approved in
February 2015 and ribociclib approved in March 2017.
|
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
Cheap drug could cut 10% of UK breast cancer deaths, charity says [The Guardian]
|
|
|
|
|
|
Bisphosphonates,
which cost around 43p a day, are used to strengthen the bones of women
diagnosed with osteoporosis. But a review in 2015 showed that they can
also reduce the number of breast cancers in postmenopausal women that
spread within 10 years after treatment and recur in the bones, where
they become incurable, from 8.8% to 6.6%.
|
|
|
|
|
|
|
5.9.5 IASLC
|
|
|
|
|
6.10 Politiques
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.11 Patients
|
|
|
|
6.13 Soins palliatifs
|
|
|
|
6.5 Médecines alternatives
|
|
|
Rigvir strikes back, or: A conversation with a Rigvir flack [Science-Based Medicine]
|
|
|
|
|
|
My
skeptical analysis of Rigvir, a “Virotherapy” from Latvia being
promoted by alternative medicine clinics as a cancer cure, caught the
attention of the International Virotherapy Center (IVC). The result was a
long and very telling e-mail exchange between its Assistant of Business
Development and myself. I post it because the arguments used in the
discussion are very telling about where the IVC is coming from when it
comes to science. Hint: It’s not a good place.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|